Back to Search Start Over

Ferritin-nanocaged copper arsenite minerals with oxidative stress-amplifying activity for targeted cancer therapy.

Authors :
Lee, Kyung Kwan
Kim, Jong-Won
Lee, Chang-Soo
Lee, Sang Cheon
Source :
Journal of Controlled Release. Sep2023, Vol. 361, p350-360. 11p.
Publication Year :
2023

Abstract

We report copper(II) arsenite-encapsulated ferritin nanoparticles (CuAS-FNs) as oxidative stress-amplifying anticancer agents. The CuAS-FNs were fabricated through CuAS mineralization in the cavity of the FNs. The formation of crystalline CuAS complex minerals in the FNs was systematically identified using various analytical tools, including X-ray photoelectron spectroscopy (XPS) and transmission electron microscopy (TEM)-associated energy-dispersive X-ray spectroscopy (TEM-EDS). The CuAS-FNs showed pH-dependent release behavior, in which the CuAS mineral was effectively retained at physiological pH, in contrast, at lysosomal pH, the CuAS complex was dissociated to release arsenite and Cu2+ ions. At lysosomal pH, the release rate of arsenite (HAsO 3 2−) and Cu2+ ions from the CuAS-FNs more accelerated than at physiological pH. Upon transferrin receptor-1-mediated endocytosis, the CuAS-FNs simultaneously released arsenite and Cu2+ ions in cells. The released arsenite ions can increase the intracellular concentration of hydrogen peroxide (H 2 O 2), with which the Cu2+ ions can elevate the level of hydroxyl radicals (·OH) via Fenton-like reaction. Thus, the CuAS-FNs could target cancer cell through the recognizing ability of FNs and kill cancer cells by amplifying the ·OH level through the synergistic activity of Cu2+ and arsenic ions. Importantly, MCF-7 tumors were effectively suppressed by CuAS-FNs without systemic in vivo toxicity. Therefore, the CuAS-FNs is a promising class of Fenton-like catalytic nanosystem for cancer treatment. Copper(II) arsenite-encapsulated ferritin nanoparticles (CuAS-FNs) were developed as targeted and oxidative stress-amplifying anticancer agents. The CuAS-FNs were rationally designed by combining the TfR-1-mediated endocytosis of the FNs and the oxidative stress amplification of the CuAS. This study paves a way for a wide range of novel cancer-specific therapeutics by systematically modulating the oxidative stress in cancer cells. [Display omitted] [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
01683659
Volume :
361
Database :
Academic Search Index
Journal :
Journal of Controlled Release
Publication Type :
Academic Journal
Accession number :
171829912
Full Text :
https://doi.org/10.1016/j.jconrel.2023.07.050